<DOC>
	<DOCNO>NCT03046862</DOCNO>
	<brief_summary>&lt; Research Hypothesis &gt; The dynamic immune system cytotoxic chemotherapy change combination immuno-oncology agent uncover . The combination Durvalumab/Tremelimumab gemcitabine/cisplatin chemotherapy feasible efficacious chemo-na誰ve biliary tract cancer . &lt; Purpose study &gt; To assess effect Durvalumab/Tremelimumab combination gemcitabine/cisplatin response rate ( RR ) chemo-na誰ve advance biliary tract cancer patient .</brief_summary>
	<brief_title>Durvalumab ( MEDI4736 ) /Tremelimumab Combination With Gemcitabine/Cisplatin Chemotherapy-na誰ve Biliary Tract Cancer</brief_title>
	<detailed_description>&lt; Rationale conducting study &gt; 1 . Rational # 1 . The incidence biliary tract cancer ( BTC ) high Korea West . ( Korea : 10 new cases/100,000 population every year , West:1-2 cases/100,100 population every year ) . Therefore , conduct clinical study BTC Korea feasible efficient . 2 . Rational # 2 The Gemcitabine/cisplatin current standard care 1st-line treatment advance BTC ( ( N Engl J Med 2010 ; 362 ( 14 ) : 1273-81 ) . No one-targeted therapy approve BTC , yet . The overall survival advance BTC cytotoxic chemotherapy 8-10 month , general . Therefore , huge unmet medical need . 3 . Rational # 3 In recent sequence data BTC show BTC patient bad prognosis significant enrichment hypermutated tumor characteristic elevation expression immune checkpoint molecule . According , immune-modulating therapy also potentially promising option patient ( Nat Genet . 2015 Sep ; 47 ( 9 ) :1003-10 . ) 4 . Rational # 4 In PDL1 ( + ) BTC , anti-PD1 Ab show promise activity monotherapy ( Bang YJ , et al . ECC/ESMO 2015 ) In one clinical study pembrolizumab , 37 89 BTC patient ( 41.6 % ) show PDL1 ( + ) tumor . Among 24 PDL1 ( + ) patient enrol treated pembrolizumab , 50 % Asian , 62.5 % ECOG 1 , 16.7 % gallbladder cancer , 80 % 3rd-line later set . Four patient show PR ( 3 Seoul National University Hospital ) , 4 patient SD , lead overall response rate 17.4 % . A total 40 % patient show tumor shrinkage . The decrease tumor size generally maintain time . This study give u evidence immune checkpoint inhibitor work BTC likewise solid tumor . 5 . Rational # 5 In recent study show combination CTLA4 inhibitor anti-PD1/PDL1 agent show enhanced clinical activity , especially , regardless PDL1 status . This combination strategy actively test many solid tumor . 6 . Rational # 6 Certain chemotherapeutic drug stimulate cancer-specific immune response induce immunogenic cell death effector mechanism ( Immunity 2013 , Annu Rev Immunol 2013 ) With cytotoxic chemotherapy , PDL-1 induce increase expression PDL1 contribute resistance cytotoxic chemotherapy . Successful eradication tumor immunogenic chemotherapy require removal immunosuppressive IgA+ , PDL1+plasmocytes ( Nature 2015 ) . More importantly , still vast majority dynamic change immune system cytotoxic chemotherapy unanswered . These support combination cytotoxic chemotherapy immuno-oncology agent include immune checkpoint inhibitor might efficacious need . 7 . Rational # 7 The advantage `` Immunotherapy cytotoxic chemotherapy '' combination ; 1 ) explore science dynamic immunologic change cytotoxic chemotherapy overcome immunotherapy 2 ) easy way incorporate current clinical practice 3 ) apply variety tumor type NSCLC , urothelial cancer . 4 ) relatively affordable `` immunotherapy target agent '' combination . Durvalumab/Tremelimumab combination cytotoxic chemotherapy test , especially BTC . &lt; Sample Size Determination &gt; Primary efficacy endpoint response rate . In BTC , response rate 1st-line gemcitabine/cisplatin chemotherapy 20 % ( 20 % BT22 clinical trial , 25 % ABC-02 clinical trial ) . Therefore , set H0 20 % , H1 40 % . Using 75 % power a-error 0.05 , total 28 patient need . When assume drop-out rate 10 % , total 31 patient enrol .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven BTC , include intrahepatic cholangiocarcinoma , extrahepatic bile duct cancer , gallbladder cancer , ampulla vater cancer Unresectable recurrent chemotherapy na誰ve unresectable recurrent cancer ( Previous expose adjuvant chemotherapy allow ) measurable lesion ECOG 0 , 1 Without previous expose immuneoncology agent include antiCTLA4 , antiPD1 , antiPDL1 , etc Adequate organ function : ANC &gt; 1500/mm3 , platelet &gt; 100K/mm3 , HgB &gt; 9 g/Dl , bilirubin &lt; 1.5 x ULN , ALT/AST &lt; 2.5 X UNL , ( case liver metastasis , &lt; 5 Xunl ) , Cr &lt; 1.5 mg/Dl Informed consent Previous treatment unresectable recurrent cancer Under immunosuppressive agent higher equivalent dose prednisone 10mg/day Uncontrolled disease current active infection , congestive heart failure , uncontrolled hypertension , unstable angina , arrhythmia , interstitial lung disease Current active pulmonary tuberculosis Current active hepatitis B hepatitis C ( simple carrier allow ) antiHIV ( + ) Pregnant , breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>